To investigate the clinical application value of sufentanil and dezocine on obese puerpera-controlled intravenous analgesia after cesarean section.

A total of 80 obese puerperas undergoing cesarean section in Puning Maternal and Child Health Hospital from March 2015 to February 2017 were included in this prospective study. Those obese puerperas were divided into the sufentanil group and the dezocine group according to the random number table method. Forty puerperas were divided into the sufentanil group with an average age of (26±5) years old; and the other 40 puerperas were divided into the dezocine group with an average age of (26±5) years old. The informed consents of all puerperas were obtained and the local ethical committee approval had been received. The two groups used patient-controlled intravenous analgesia after cesarean section, of them the sufentanil group patients used sufentanil for analgesia (sufentanil 2μg/kg + tropisetron 10 mg + saline up to 100 ml) and the dezocine group patients used dezocine for analgesia (dezocine 0.5 mg/kg + tropisetron 10 mg + saline up to 100 ml). The infusion speed of analgesia pump was set at 2 ml/h, the additional dosage was 2 ml per time and the locking time was 15 minutes. The pain score, sedation score and comfort score after analgesia at 4, 8, 12, 24 and 48 h postoperatively, and the number of adding analgesic drug and the incidence of adverse reaction within 24 h after cesarean section were compared between the two groups. The pain score, sedation score, comfort score after analgesia and the number of adding analgesic drug between the two groups were compared using t test; and the comparison of the incidence of adverse reaction was conducted using χ² test.

The VAS pain score, Ramsay sedation score, BCS comfort score and incidence of adverse reaction at 4, 8, 12, 24 and 48 h after cesarean section had no statistic difference between the two groups (P>0.05). However, the number of adding dezocine in the dezocine group was (10.3±4.2), which was significantly more than (6.4±2.8) of adding sufentanil in the sufentanil group (P<0.05).

Sufentanil has a better analgesic effect than dezocine on obese puerpera after cesarean section, therefore helps to improve the treatment satisfaction and postoperative recovery rate of obese puerpera.